本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Bicara Therapeutics

23.90
-0.4900-2.01%
成交量:49.64萬
成交額:1,202.92萬
市值:15.82億
市盈率:-7.69
高:25.56
開:24.73
低:23.77
收:24.39
52周最高:30.99
52周最低:10.30
股本:6,617.29萬
流通股本:5,230.21萬
量比:1.00
換手率:0.95%
股息:- -
股息率:- -
每股收益(TTM):-3.1097
每股收益(LYR):-2.5230
淨資產收益率:-41.01%
總資產收益率:-26.14%
市淨率:3.37
市盈率(LYR):-9.47

資料載入中...

公司資料

公司名字:
Bicara Therapeutics
交易所:
NASDAQ
成立時間:
2018
員工人數:
103
公司地址:
116 Huntington Avenue,Suite 703,Boston,Massachusetts,United States
郵編:
02116
電話:
傳真:
- -
簡介:
Bicara Therapeutics Inc.於2018年12月12日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物製藥公司,專註於為實體瘤開發雙功能療法。其主要候選藥物ficerafusp alfa同時靶向EGFR和TGF-β通路,目前正在針對頭頸部鱗狀細胞癌進行一項關鍵性試驗。

董事

名稱
職位
Claire Mazumdar
Chief Executive Officer and Director
Michael Powell
Chairperson of the Board
Ryan Cohlhepp
President, Chief Operating Officer and Director
Carolyn Ng
Director
Christopher Bowden
Director
Heath Lukatch
Director
Jake Simson
Director
Kate Haviland
Director
Kiran Mazumdar Shaw
Director
Nils Lonberg
Director
Scott Robertson
Director
Vijay Kuchroo, D.V.M
Director

股東

名稱
職位
Claire Mazumdar
Chief Executive Officer and Director
Ryan Cohlhepp
President, Chief Operating Officer and Director
Ivan Hyep
Chief Financial Officer
David Raben
Chief Medical Officer
Lara Meisner
Chief Legal Officer